Pembrolizumab and Severe Hypertriglyceridemia Requiring Apheresis: An Immune-Related Adverse Event

J Oncol Pract. 2019 Nov;15(11):613-614. doi: 10.1200/JOP.19.00245. Epub 2019 Oct 3.

Authors

Malvi Thakker¹, Kalimullah Quadri¹, Ankuri Desai¹, Wajiha Illyas¹, Min Young Kim¹, Sanket Desai², Christina Rager¹

Affiliations

¹ Mather Hospital - Northwell Health, Westbury, NY.
² Stony Brook University, Stony Brook, NY.

PMID: 31580769
DOI: 10.1200/JOP.19.00245

No abstract available

Publication types

Case Reports

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects*
Antineoplastic Agents, Immunological / adverse effects
Blood Component Removal / methods*
Brain Neoplasms / drug therapy*
Brain Neoplasms / secondary
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / pathology
Female
Humans
Hypertriglyceridemia / chemically induced
Hypertriglyceridemia / pathology
Hypertriglyceridemia / therapy*
Lung Neoplasms / drug therapy*
Lung Neoplasms / pathology
Lymphatic Metastasis
Mediastinal Neoplasms / drug therapy*
Mediastinal Neoplasms / secondary
Middle Aged
Prognosis

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
pembrolizumab